[A Case of Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy]

Gan To Kagaku Ryoho. 2017 Jul;44(7):599-602.
[Article in Japanese]

Abstract

A 73-year-old woman diagnosed with unresectable pancreatic cancer received weekly gemcitabine(GEM)plus albuminbound paclitaxel(nab-PTX)therapy. Four months after nab-PTX therapy was initiated, she presented with a rapidly decreasing vision in her left eye at an ophthalmology clinic. On admission, her visual acuity was decreased, and optical coherence tomography(OCT)revealed a cystoid macular edema(CME)only in her left eye. She discontinued the nab-PTX therapy immediately. Her visual acuity improved on follow-up 6 months later. The CME finding on OCT was reduced but not completely resolved. CME is a rare adverse event induced by nab-PTX therapy, with only 14 cases reported since 2008. In most of the reported cases, the patients had breast cancer, and this is the first reported case of CME in a patient with pancreatic cancer. The time to CME onset from starting nab-PTX therapy was reported to range from3 to 30months, but the predilection time has not been clarified. Many reports indicated that symptoms improved in a short period after discontinuation of nab-PTX therapy, but effective treatment was not established, except discontinuation of nab-PTX therapy. In daily medical treatment, the incongruity of the ophthalmologic domain should be confirmed for early detection of CME.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Albumin-Bound Paclitaxel / adverse effects*
  • Albumin-Bound Paclitaxel / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Female
  • Humans
  • Macular Edema / chemically induced*
  • Pancreatic Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Albumin-Bound Paclitaxel
  • Antineoplastic Agents